10 High Growth S&P 500 Stocks to Buy Now

4. Insulet Corporation (NASDAQ:PODD)

Truist on February 19, 2026, lowered its price target on Insulet Corporation (NASDAQ:PODD) to $360 from $390 and maintained a Buy rating. The firm said Insulet delivered another strong Q4 beat, supported by broad global strength in Omnipod 5 as the company builds on its first-mover advantage in Type 2 diabetes and leverages direct-to-consumer marketing to drive new patient starts.

The same day, Goldman Sachs analyst David Roman reduced the price target to $326 from $363 and kept a Buy rating. David Roman said the U.S. insulin pump market posted strong Q4 growth, with Type 2 adoption adding to continued Type 1 uptake, while the OUS market delivered mid-20s FX-neutral growth. Goldman Sachs added that early-stage Type 2 adoption, conversion from multiple daily injections, and international expansion position Insulet to maintain a leading share, even as the current valuation appears more cautious than underlying fundamentals.

On February 18, 2026, Insulet reported Q4 adjusted EPS of $1.55 versus $1.46 consensus and revenue of $783.8M compared with $768.73M consensus. President and CEO Ashley McEvoy said, “We ended the year with another excellent quarter,” citing innovation, scale, and disciplined execution, and added that Insulet is confident in its ability to expand adoption across both Type 1 and Type 2 diabetes in 2026.

Insulet Corporation (NASDAQ:PODD) develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.